BRIDGEWATER, N.J. - VYNE Therapeutics Inc. (NASDAQ:VYNE), a biopharmaceutical company focused on developing treatments for immuno-inflammatory conditions, has been granted a UK patent for its VYN202 program compound. The patent, awarded by the United Kingdom's Intellectual Property Office, is set to expire in June 2042.
The patent, GB Patent No. 2621505, covers the composition of matter for a compound within the VYN202 program, which is part of VYNE's portfolio of bromodomain & extra-terminal (BET) domain inhibitors. According to the company's President and CEO, David Domzalski, this patent is a significant development for VYN202, which is touted as a potent and BD2-selective BET inhibitor.
VYN202 is an orally administered small molecule BET inhibitor with potential selectivity and potency that could offer a convenient non-biologic treatment option for managing immuno-inflammatory diseases. These conditions are often characterized by harmful levels of inflammatory signaling activity.
BET proteins are crucial in regulating gene transcription through epigenetic interactions, influencing the activation of B cells and T cells, which can lead to inflammatory processes. BET inhibitors like VYN202 aim to block the transcription of pro-inflammatory cytokines and may have applications in treating a variety of immuno-inflammatory and fibrotic diseases, as well as certain neoplastic disorders.
The patent originates from a Patent Cooperation Treaty (PCT) application filed by Tay Therapeutics Limited, which is exclusively licensed to VYNE. It represents the first national application from the PCT filing to be granted.
This announcement is based on a press release statement and includes forward-looking statements subject to risks and uncertainties. VYNE's ability to secure additional patents and the potential efficacy of VYN202 as a broad therapy for immune-mediated diseases are forward-looking statements that involve known and unknown risks. These statements are not guarantees of future performance, and actual results may differ materially.
VYNE continues to pursue intellectual property protection in additional jurisdictions as it advances its BET inhibitor pipeline. The company's mission remains focused on improving patient outcomes by developing innovative therapies for the treatment of immuno-inflammatory conditions.
In other recent news, VYNE Therapeutics has commenced a Phase 1a trial for its drug candidate VYN202, an orally administered BET inhibitor. The trial, which recently started dosing its first healthy volunteers, will evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of VYN202.
The study is a double-blind, placebo-controlled trial, enrolling approximately 64 healthy adult participants across multiple cohorts. H.C. Wainwright maintained its Buy rating on VYNE following this announcement, expressing optimism about the drug's clinical and value-generating potential.
The results from this initial phase of the trial are expected to be released in the second half of 2024. If successful, VYNE plans to proceed with a Phase 1b trial involving patients with plaque psoriasis and adult-onset rheumatoid arthritis, with top-line results potentially disclosed as early as the second half of 2025. These are the latest developments in VYNE Therapeutics' broader InhiBET platform, which includes both VYN201 and VYN202.
InvestingPro Insights
VYNE Therapeutics Inc. has recently achieved a milestone with the granting of a UK patent for its VYN202 program compound, potentially bolstering its intellectual property portfolio and future prospects. To provide a more comprehensive picture of the company's financial health and market performance, here are some key insights from InvestingPro:
InvestingPro Data:
- Market Cap (Adjusted): 32.69M USD
- P/E Ratio (Adjusted) last twelve months as of Q1 2024: -1.14
- Revenue Growth last twelve months as of Q1 2024: 6.28 %
InvestingPro Tips:
- VYNE holds more cash than debt on its balance sheet, indicating a solid liquidity position that could support its ongoing research and development efforts.
- The company has experienced a significant return over the last week with a 14.8% increase, which may reflect market optimism following the patent news.
While these insights provide a snapshot of VYNE's financial metrics and stock performance, there are additional InvestingPro Tips available for those who want to delve deeper into the company's prospects.
For instance, it is worth noting that analysts do not anticipate the company will be profitable this year, and VYNE has not been profitable over the last twelve months. Moreover, the price has fallen significantly over the last five years, and the company does not pay a dividend to shareholders, which could be important considerations for potential investors.
For more detailed analysis and further tips on VYNE, consider subscribing to InvestingPro. Use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. With this subscription, you can access a total of 8 InvestingPro Tips for VYNE, which could provide valuable insights for your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.